Share: 
Status: 
Active
Rating: 
No votes yet
0

On Demand 2016 Workshops

Course description

You can earn up to 48 AMA PRA Category 1 Credit(s)™. 

This collection consists of all the concurrent workshop sessions that are suitable for online delivery. Now you don't have to decide which session to select, you can watch them all!
48 Credits / $335 members / $439 non-members

Package includes:

  • W1 - Insect Allergy Update
  • W3 - Food Challenges in Practice: Safe and Simplified
  • W4 - When Cough, Wheeze or Dyspnea Are Not Asthma
  • W5 - Drug Allergy Options Beyond Avoidance: Where the Allergist Matters
  • W6 - Office Procedures for Allergic Skin Diseases
  • W8 - Advocacy Council 2016 Update on Coding: What You Need to Know
  • W9 - Immunotherapy 2016: SCIT, SLIT and More!
  • W10 - Gadgets & Gizmos: Using Technology in Your Practice
  • W11 - Food Allergies: What's New in Prevention and Treatment
  • W13 - Difficult to Control Rhinitis and Rhinosinusitis: What the Experts Do
  • W14 - Living With An Itch: A Practical Approach to Diagnosis and Treatment
  • W16 - Advocacy Council: Update on Legal / Regulatory Issues
  • W18 - Essentials of Sterile Compounding for the Allergy Practice
  • W19 - Surviving and Optimizing in the World of EMR
  • W20 - Diagnostic Testing for Food Allergy: Old and New
  • W21 - Integrative Medicine in the Allergist's Office: Science and in Practice
  • W22 - Skin Biopsy of the Allergist: How to Perform and Interpret
  • W23 - PBL Workshop: Laboratory Evaluation of the Immune System
  • W25 - Difficult Cases in Primary Immune Deficiency
  • W26 - Fat Lips and Swollen Throats: What Are the Facts?
  • W27 - Management of Asthma: Beyond Just Medications
  • W28 - Atopic Dermatitis In-depth
  • W29 - Alcohol, Marijuana, Hookah and Additive Allergies
  • W30 - Hyper IgE and Hypereosinophilia: When to Worry and How to Evaluate
  • W31 - Delayed Hypersensitivity Drug Reactions: Dilemmas in Diagnosis and Treatment
  • W32 - Eosinophilic Esophagitis and Other Swallowing Disorders
  • W33 - Primary Immune Deficiency: Antibiotics and Other Treatments
  • W34 - Allergies in Infants and Very Young Children

Release Date: 12/01/2016
Expiration Date: 11/30/2019

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 30 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning objectives: 
  • Recognize the most common insects that cause reaction in humans, as well as the reactions these insects cause;
  • Develop an evaluation and treatment plan, as well as evaluate how to work with local emergency departments for aftercare of patients seen;
  • Review management of insect allergy with emphasis on the What’s New section of the upcoming Insect PP;
  • Demonstrate competence in allergen selection and administration in successful cluster and rush immunotherapy regimens;
  • Identify patient indications, immunologic mechanisms, and special considerations related to cluster and rush immunotherapy delivery;
  • Describe how to perform an oral food challenge;
  • Review indications for an oral food challenge and reasons for deferment;
  • Identify the clinical characteristics that support asthma as the cause of cough, wheeze, or dyspnea;
  • Recognize that not all coughs or wheezes are asthma;
  • Differentiate symptoms common for asthma from other causes of those symptoms;
  • Discuss diagnostic tests and management options for patients with reported hypersensitivity to antibiotics, including beta-lactams, macrolides, quinolones and sulfonamides;
  • Discuss diagnostic tests and management options for patients with reported hypersensitivity to aspirin and NSAIDs;
  • Discuss diagnostic tests and management options for patients with reported hypersensitivity to chemotherapeutic drugs.
  • Describe the different tests for physical urticarial and the indications for skin biopsy and interpretation of skin biopsy results;
  • Discuss the indications and interpretation of the standard epicutaneous patch testing and the utility of repeat open application testing;
  • Demonstrate the application of epicutaneous patch testing;
  • Describe the major anatomical findings in the upper airway;
  • Identify normal and abnormal anatomy, disease presentations and post-op findings;
  • Identify indications for use of the rhinoscope in the allergist’s office;
  • Explain why the conversion to ICD-10 occurred and why correct coding is important;
  • Identify and coordinate ICD-10 and CPT codes;
  • Identify ICD-10 codes that were not used in the past, but that may be helpful in the future;
  • Identify new ICD-10 codes that may be needed in the future;
  • Explain the differences between subcutaneous, sublingual and other forms of allergy immunotherapy for the purpose of therapeutic extracts related to patient care, including health care outcomes research which involves benefits related to the optimal dosing and use of immunotherapy;
  • Write prescriptions for immunotherapy which contain safe and effective doses of each component according to current guidelines and best clinical practice for the benefit of patient care;
  • Discuss various technology options that can be integrated within their practice;
  • Effectively search for and utilize medical apps for clinical care and patient education;
  • Find resources to stay updated/get involved with the medical technology community;
  • Examine the current guidelines for the prevention of food allergy;
  • Compare therapeutic strategies under investigation for food allergy;
  • Describe the major anatomical structures of the nasal, pharyngeal and glottic areas as visualized during examination with the fiber-optic rhinolaryngoscope;
  • Describe variations of normal seen in this hands-on session;
  • Demonstrate the proper handling and initial skills needed to perform a comprehensive upper airway examination with a fiberoptic endoscope;
  • Describe newer techniques for the diagnosis and management of rhinitis and rhinosinusitis in the clinical setting;
  • Discuss complementary methods for the treatment of rhinitis and rhinosinusitis as well as novel therapeutics which have been shown to be safe and effective for treatment of these common conditions;
  • Develop strategies for allergist and dermatologist co-management of patients with itch;
  • Outline an evidence-based therapeutic ladder for management of itch;
  • Describe the major anatomical structures of the nasal, pharyngeal and glottic areas as visualized during examination with the fiber-optic rhinolaryngoscope;
  • Describe variations of normal seen in this hands-on session;
  • Demonstrate the proper handling and initial skills needed to perform a comprehensive upper airway examination with a fiberoptic endoscope;
  • Explain why the RUC reviews codes and how its decisions can impact allergy;
  • Adapt these new regulatory requirements to their practices;
  • Explain why developing alternative payment models is important to allergists and use Advocacy Council resources.
  • Better navigate the recesses of the nasal airway and larynx;
  • Demonstrate more advanced skills needed to perform a comprehensive upper airway examination with a fiber-optic endoscope;
  • Identify the major anatomical structures of the nasal, pharyngeal and glottic areas as visualized during examination with the fiber-optic rhinolaryngoscope;
  • Describe variations of normal if seen when participants examine one another;
  • Describe requirements of USP 797 and relevant guidelines for allergen extract compounding;
  • Demonstrate the technique of sterile compounding required in office-based practice;
  • Define best practices for implementing an EHR in the practice;
  • Identify the root causes of common issues with EHRs in the practice;
  • Select appropriate components to measure in patients with suspected food allergy, focusing on peanut;
  • Recommend appropriate treatment based on the results of the component tests;
  • Describe practical services that meet this unique need and how they are billed;
  • Describe the components of what is needed for a comprehensive assessment of the patient’s body, mind and spirit;
  • Discuss challenges/opportunities for identifying referrals to nutritionists, exercise professionals and clinical psychologists/social workers for mindfulness training;
  • Perform a skin biopsy with proper technique and tools;
  • Recognize possible complications, adverse effects and limitations of skin biopsy;
  • Identify various common interpretations of skin biopsy;
  • Interactively discuss a patient with recurrent respiratory infections and the appropriate office evaluation;
  • Review the rationale for new tests for immunodeficiency;
  • Become aware of new therapeutic options for the patient discussed;
  • Recognize how basic science and clinical research has identified distinct pathophysiologic endotypes in severe asthma;
  • Describe which patients are candidates for therapy with new biologic agents approved for use in asthma;
  • Discuss differences in presentation and treatment of children and adults with severe asthma;
  • Identify appropriate evaluation of patients with suspected immune deficiency;
  • Learn appropriate strategies for managing patients with primary immune deficiencies;
  • Discuss the workup and treatment approaches to patients with types 1 and 2 hereditary angioedema (HAE);
  • Discuss the pathophysiology, workup and treatment of histamine-mediated urticaria/angioedema and distinguishing features from type 3 HAE;
  • Review some of the evidence for the nonpharmacologic (integrative medical) approach to asthma management, including complementary medicine (CM), lifestyle and mind-body strategies;
  • Discuss some of the practical and safety issues involved, i.e. exercise, smoking cessation, diet and lifestyle changes;
  • Recognize how to offer, present and follow these options to patients using a shared decision-making approach.
  • Outline an evidence-based therapeutic ladder for management of atopic dermatitis;
  • Recognize pitfalls in successful management/ reasons for treatment failure;
  • Recognize the clinical symptoms associated with alcohol sensitivity reactions and its evaluation and management;
  • Give insight into the health implications of water pipe tobacco smoking/hookah and the use of marijuana;
  • Discuss the presenting symptoms associated with food additive allergy;
  • Recognize clinical manifestations of hypereosinophilic disorders;
  • Choose appropriate diagnostic tests in the evaluation of hypereosinophilia;
  • Discuss common delayed drug hypersensitivity reactions presenting to the allergist/immunologist;
  • Describe how to perform drug skin testing, including intradermal and patch testing;
  • Discuss the pathophysiology and differential diagnosis of eosinophilic esophagitis (EoE) and other similar swallowing disorders;
  • Discuss the diagnostic options and evolving treatments for EoE;
  • Interactively discuss a patient with recurrent respiratory infections and the appropriate office evaluation;
  • Appreciate the importance of antibiotic prophylaxis in the management of immunodeficiency;
  • Recognize the current and evolving treatments for primary immune deficiency;
  • Discuss new and current recommendations for diagnosis and management of childhood asthma;
  • Apply new and current diagnostic and therapeutic options in respiratory allergies and other conditions in pediatric patients.
Credits
  • 48.00 AMA PRA Category 1 Credit™
  • 48.00 Attendance
Additional information
Disclosure: 

James M. Tracy, DO, FACAAI -- Consultant/Advisor: Shire; Speaker: UptoDate

David B. Engler, MD, FACAAI  -- Speaker: Boehringer Ingelheim; Ownership Interest: Gilead, Regeneron

Mike Tankersley, MD, FACAAI -- Speaker: Merck

Rima A. Rachid, MD -- Consultant/Advisor: Aimmune Therapeutics; Supported/Contracted Research: Aimmune Therapeutics

Hugh A. Sampson, MD, FACAAI -- Consultant/Advisor: Allertein, Danone Scientific Advisory Board, Thermo Fisher Scientific; Patent Holder/Royalty/IPR: Herbs Spring, LLC; Employee: DBV Technologies; Ownership Interest: Allertein, DBV Technologies, Herbs Spring, LLC

Rohit K. Katial, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Meda, Teva; Speaker: Meda, Teva

Luz S. Fonacier, MD, FACAAI -- Consultant/Advisor: Regeneron, Church and Dwight; Speaker: Baxter; Supported/Contracted Research:Baxter, Genentech, Merck

Sharon E. Jacob, MD -- Consultant: Johnson and Johnson, Skintifique; Speaker & Independent Investigator- Smartpractice, USA (makers TRUE Test); Founder-CEO, Dermatitis Academy, free educational online resource

J. Allen Meadows, MD, FACAAI -- Speaker: Meda

John J. Oppenheimer, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Genentech, GlaxoSmithKline, Meda, Mylan, Novartis, Annals of Allergy, ABAI, Up to date, Teva; Supported/ Contracted Research: AstraZeneca, Genentech, MedImmune, Sanofi

Jay M. Portnoy, MD, FACAAI -- Consultant/Advisor: Boehringer Ingelheim; Speaker: Mylan, Thermo Fisher Scientific

Nabeel Farooqui, MD -- Speaker: Merck

Julie Wang, MD, FACAAI -- Consultant/Advisor: JDP Therapeutics, Aimmune; Supported/Contracted Research: JDP Therapeutics

Jonathan A. Bernstein, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Biocryst, Boehringer Ingelheim, CSL Behring, Dyax, GlaxoSmithKline, Meda, Shire; Speaker: Baxter, CSL Behring, Dyax, Greer, Novartis, Shire; Supported/ Contracted Research: AstraZeneca, Biocryst, Boehringer Ingelheim, CSL Behring, Dyax, Forest, Genentech, Gilead, GlaxoSmithKline, Greer, MedImmune, Meda, Merck, Novartis, Shire, Stallergenes, Teva

Anju T. Peters, MD -- Consultant/Advisor: Celgene, Greer; Speaker: Celgene, Greer; Supported/Contracted Research: Sanofi

Peter A. Lio, MD -- Consultant/Advisor: Anacor, Galderma, Johnson & Johnson, IntraDerm Pharmaceuticals, Mission, Exeltis, Pierre Fabre, Regeneron, Valeant; Speaker: Anacor, Mission, Pierre Fabre, Regeneron, Valeant

Gil Yosipovitch, MD -- Consultant/Advisor: Anacor, Celgene, Eli Lilly, Johnson & Johnson, Pfizer, Regeneron; Supported/Contracted Research: Allergan, GlaxoSmithKline, Pfizer, Roche

J. Allen Meadows, MD, FACAAI -- Speaker: Meda

Gary Steven, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Meda; Speaker: Aerocrine, AstraZeneca, Boehringer Ingelheim, Greer, Meda, Merck, Stallergenees; Supported/Contracted Research: AstraZeneca, Circassia, Genentech, GlaxoSmithKline, Merck, Mylan, Novartis, Roche, Teva

Marcella R. Aquino, MD, FACAAI -- Supported/Contracted Research: Genentech, Merck, Novartis, Roche

Ray S. Davis, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Baxter, Genentech, Meda, Merck, Mylan, Sunovion, Teva; Speaker: AstraZeneca, Meda, Merck, Mylan, Teva

Leonard B. Bacharier, MD, FACAAI -- Consultant/Advisor: Boehringer Ingelheim, DBV Technologies, Genentech, Meda, Merck, Novartis, Sanofi, Teva, Vectura; Speaker: AstraZeneca, Boehringer Ingelheim, Merck, Teva

Reynold A. Panettieri, MD -- Consultant/Advisor: AstraZeneca, Genentech, Gilead, Teva; Speaker: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi, Teva; Supported/Contracted Research: Boston Scientific, MedImmune, Teva

Lisa J. Kobrynski, MD, MPH, FACAAI -- Consultant/Advisor: Baxter, CSL Behring; Supported/Contracted Research: Baxter, Grifols

William R. Lumry, MD, FACAAI -- Consultant/Advisor: Biocryst, CSL Behring, Dyax, Genentech, Medical Advisory Board–Hereditary Angioedema Association, Roche, Salix, Shire; Speaker: CSL Behring, Dyax, Genentech, Greer, Meda, Medical Advisory Board–Hereditary Angioedema Association, Salix, Shire, Teva; Supported/Contracted Research: ADMA Biologics, Biocryst, CSL Behring, Circassia, Cytos, Dyax, Genentech, Grifols, Kedrion, Mylan, Novartis, Perrigo, Roche, Shire, Teva, Therapure; Board Member for profit organization: Medical Advisory Board–Hereditary Angioedema Association

Richard W. Weber, MD, FACAAI -- Speaker: AstraZeneca, Meda, Merck; Supported/Contracted Research: GlaxoSmithKline, Regeneron

Don A. Bukstein, MD, FACAAI -- Speaker: Aerocrine, AstraZeneca, Boston Scientific, Circassia, Faes Farma, Genentech, Meda, Merck, Mylan, Novartis, Stallergenes, Teva

Mark Boguniewicz, MD, FACAAI -- Consultant/Advisor: Regeneron; Supported/ Contracted Research: Anacor, Regeneron

David A. Khan, MD, FACAAI -- Speaker: Genentech

Eric M. Macy, MD, FACAAI -- Supported/Contracted Research: ALK

Seema S. Aceves, MD, PhD -- Consultant/Advisor: Receptos, Meritage consulting contract now completed

Jonathan M. Spergel, MD, PhD, FACAAI -- Consultant/Advisor: DBV Technologies

Mark M. Ballow, MD, FACAAI -- Consultant/Advisor: Baxter, Grifols; Speaker: Baxter, CSL Behring; Supported/Contracted Research: CSL Behring, Kedrion, Prometic BioScience

Francisco A. Bonilla, MD, PhD -- Consultant/Advisor: Baxter, CSL Behring, Grifols, Gerson–Lehrman Group, Grand Rounds Health; Patent Holder/Royalty/IPR: UpToDate in Medicine

Chitra Dinakar, MD, FACAAI -- Consultant/Advisor: Meda, Teva; Speaker: Boehringer Ingelheim, Teva

Todd A. Mahr, MD, FACAAI -- Consultant/Advisor: Meda, Teva; Speaker: Aerocrine, AstraZeneca, GlaxoSmithKline, Meda, Merck, Teva; Supported/Contracted Research: AstraZeneca

The following have no financial relationship to disclose:

Theodore M. Freeman, MD, FACAAI

Stephen C. Lazarus, MD

Aleena Banerji, MD

Roland Solensky, MD, FACAAI

Hannelore A. Brucker, MD, FACAAI

David R. Naimi, DO

Patricia C. Fulkerson, MD, PhD

Princess Ogbogu, MD

Jerald W. Koepke, MD, FACAAI

Seong H. Cho, MD

Gary N. Gross, MD, FACAAI

Vesselin Dimov, MD

Sami L. Bahna, MD, DrPH, FACAAI

Kevin R. Murphy, MD, FACAAI (SC)

Grant C. Olson, MD, FACAAI

Donald W. Pulver, MD, FACAAI

C. Ross Westley, MD, FACAAI

Bryan L. Martin, DO, FACAAI

Michael R. Nelson, MD, PhD, FACAAI

Gerald B. Lee, MD

Maeve E. O’Connor, MD, FACAAI

Amal H. Assa’ad, MD, FACAAI

Morna J. Dorsey, MD, MMS

David R. Weldon, MD, FACAAI

Sean A. McGhee, MD

Marianne Frieri, MD, PhD, FACAAI

Gailen D. Marshall, MD, PhD, FACAAI

Course summary
Available credit: 
  • 48.00 AMA PRA Category 1 Credit™
  • 48.00 Attendance
Course opens: 
12/01/2016
Course expires: 
11/30/2019
Cost:
$439.00
Please login or create an account to take this course.

Payment required

You must purchase this course.